The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.75
Bid: 15.50
Ask: 16.00
Change: -0.50 (-3.08%)
Spread: 0.50 (3.226%)
Open: 16.25
High: 16.25
Low: 15.70
Prev. Close: 16.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Venture Life Sees Order Boost For Sanitiser

Tue, 09th Jun 2020 13:25

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Venture Life Group PLC - Berkshire-based self care products maker - Says order book "significantly ahead" of year prior. Reports solid demand for hand sanitiser gel product. Extends relationship with Alliance Pharma, becoming second manufacturer of Wiltshire-based pharmaceutical firm's Kelo-Cote scar gel products.

----------

Better Capital PCC Ltd - Guernsey-based investment company - To take write-down on valuation of investment in Everest, a British windows and home improvement firm. Better Capital's Fund II has invested GBP3.2 million into creation of Everest 2020, which bought assets of Everest Ltd, including its order pipeline. Pre-packaged administration deal rescued over 400 jobs at Everest and ensures existing orders can be completed.

----------

Plaza Centers NV - Netherlands-based property firm - Says buyer of company's stake in a shopping and entertainment centre in Belgrade will pay firm EUR830,000 to settle purchase. Plaza Centers to increase amount paid to bondholders to EUR500,000 from EUR250,000 at next payment date on July 1.

----------

Altyn PLC - gold miner in Kazakhstan - Says "positive momentum" continuing in second quarter with annualised monthly production run rate of 600,000 tonnes per year achieved in April and May. Altyn adds this represents 60% growth quarter-on-quarter. Altyn explains gold recovery grades also improved and beating budgeted targets. Seeing pick up in interest among investors, so far raised USD3.2 million out of USD10 million maximum in Astana Stock Exchange bond issue.

----------

Ormonde Mining PLC - Spain-focused natural resources - Cost-effective work programme at existing Spanish gold assets being advanced. Continuing to assess prospective projects, with 100 reviewed to date and a handful shortlisted "for further active consideration".

----------

Chaarat Gold Holdings Ltd - Gold miner in Armenia and Kyrgyz Republic - Targets 300,000 ounces per year production from 2026 at Kyzyltash deposit, Kyrgyz Republic. Lays out plans to get there, beginning with updated feasibility study in 2022, project financing in 2023 before construction follows in 2024 and 2025.

----------

Rockfire Resources PLC - Australia-focused gold and copper explorer - Reports results of 3D magnetic imagery at Plateau gold deposit in Lighthouse tenements, Australia. Probe confirms gold target beyond a depth of 600 metres. Field crew now in place to prepare for start of drilling.

----------

Star Phoenix Group Ltd - oilfield services firm in Trinidad - Yet to receive outstanding USD1.5 million payment from LandOcean Energy Services Co Ltd over sale of Range Resources Trinidad Ltd. Agreed deadline for payment was Monday and Star Phoenix has made "numerous attempts" to secure cash. Company now working with legal advisers.

----------

Destiny Pharma PLC - Brighton-based biotechnology firm - Awarded grant for research with Cardiff University to assess whether its DPD‑207, XF-70 and XF-73 drug compounds can treat fungal infections. Financial terms of partnership not disclosed.

----------

PureTech Health PLC - biotherapeutics firm based in Massachusetts - Reports "positive" data from founding company Vedanta Biosciences Inc's two Phase 1 studies of VE202 candidate for inflammatory bowel disease. Study shows VE202 was "safe and well-tolerated at all doses".

----------

Hutchison China Meditech Ltd - Hong Kong-based biopharmaceutical firm - Enters into agreement with Guangzhou government for planned return of Hutchison's remaining 34 years land-use rights of about 30,000 square meters of unused site. Hutchison will secure USD95 million for the return of the site.

----------

iEnergizer Ltd - Guernsey-based IT services firm - Reports strong performance in six months to March 31, its year end date. Says focus remained on high margin work and revenue set to be in line with market expectations but earnings before interest, taxes, depreciation and amortisation beating forecasts. Reaffirms commitment for progressive dividend policy.

----------

Redcentric PLC - London-based IT services provider - Extends loan facilities until June 30, 2022. Extended loan is a GBP17.5 million revolving credit facility provided by Barclays Bank PLC and National Westminster Bank PLC.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2019 16:06

Destiny Pharma Says New Guidelines Prove Lead Product Marketability

Destiny Pharma Says New Guidelines Prove Lead Product Marketability

Read more
2 Dec 2019 15:57

Destiny Pharma Appoints Former Polyphor Medical Chief To Board

Destiny Pharma Appoints Former Polyphor Medical Chief To Board

Read more
16 Oct 2019 14:48

Destiny Pharma pleased with latest XF-73 results at it proceeds with next phase

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma reported on the publication of results from a positive phase 1 clinical study in 60 healthy United States volunteers using a nasal gel formulation of its lead drug, XF-73 (exeporfinium chloride), on Wednesday.

Read more
16 Oct 2019 11:36

Destiny Pharma's XF-73 Associated With Reduced Staphylococcus Aureus

Destiny Pharma's XF-73 Associated With Reduced Staphylococcus Aureus

Read more
23 Sep 2019 16:09

Destiny Pharma Says Non-Executive Joe Eagle Steps Down From Board

Destiny Pharma Says Non-Executive Joe Eagle Steps Down From Board

Read more
23 Sep 2019 12:12

Destiny Pharma Interim Loss Narrows On Smaller Share Option Charge

Destiny Pharma Interim Loss Narrows On Smaller Share Option Charge

Read more
10 Sep 2019 14:16

Destiny Pharma Collaboration With University Of Sheffield Wins Funding

(Alliance News) - Destiny Pharma PLC on Tuesday said it has been awarded a grant along with the University of Sheffield for their research collaboration on drug-resistant infections.Shares

Read more
9 Apr 2019 11:17

Destiny Pharma Annual Loss Doubles On Higher Costs, Confident Outlook

LONDON (Alliance News) - Destiny Pharma PLC on Tuesday reported a significantly widened annual loss as expenses surged in the run-up to the development of its lead candidate.For 2018, the a

Read more
9 Apr 2019 09:32

Destiny Pharma 'well funded' despite wider loss

(Sharecast News) - Destiny Pharma on Tuesday reported a wider annual loss as it increased research and development costs, although the company is "well funded" through to the second half of next year.

Read more
2 Apr 2019 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 3 April AAFull Year ResultsCMC MarketsTrading GroupTrading Year Year 4

Read more
27 Mar 2019 11:53

Destiny Pharma, MedPharm To Develop New XF-Platform Drug Formulations

LONDON (Alliance News) - Destiny Pharma PLC on Wednesday said it has partnered with MedPharm to develop new formulations of its XF-platform compounds.MedPharm is a contract provider of and

Read more
28 Jan 2019 11:46

Destiny Pharma Gets Positive Results From Second Phase Trial Of XF-73

LONDON (Alliance News) - Destiny Pharma PLC on Monday reported positive results in a second phase 1 clinical study examining the anti-irritation features of its XF-73 nasal gel.The study, a

Read more
28 Jan 2019 10:39

Destiny Pharma sees success in latest trial of XF-73 nasal gel

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma announced positive data and the non-irritant classification for its XF-73 nasal gel on Monday.

Read more
25 Jan 2019 10:58

Destiny Pharma leaps on £1.6m grant and UK-China collaboration

(Sharecast News) - Destiny Pharma jumped on Friday after being awarded funding of up to £1.6m from a collaboration established under the UK-China AMR grant fund.

Read more
25 Jan 2019 09:53

Destiny Pharma Gets Funding For Antimicrobial Resistance Research

LONDON (Alliance News) - Destiny Pharma PLC said Friday that it has secured a GBP1.6 million grant for examining novel drugs to prevent, control and eradicate life threatening bacteria or without

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.